Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

Exhibit 99.1 CONSOLIDATED FINANCIAL STATEMENTS AS AT AND FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 and 2021 (Expressed in U.S. Dollars) REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM TO THE SHAREHOLDERS AND DIRECTORS OF XORTX THERAPEUTICS INC. Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated statements of financial position of Xortx Therapeutics Inc. (the "Company") and its subsidiaries as of December 31, 2023 and 2022 and January 1, 2022, and the rel ...

Exhibit 99.1 CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS As at and for the three and nine months ended September 30, 2023 and 2022 (Unaudited - expressed in U.S. Dollars) XORTX THERAPEUTICS INC. Condensed Interim Consolidated Statements of Financial Position (Unaudited - expressed in U.S. Dollars) | | | | December 31, | January 1, | | --- | --- | --- | --- | --- | | | | | 2022 | 2022 | | | | September 30, | Restated | Restated | | | Note | 2023 | (Note 2) | (Note 2) | | | | $ | $ | $ | | Assets | | ...

Election Results - Allen Davidoff received 3,432,152 votes (52.65%) for his election as director, while 3,087,324 votes (47.36%) were withheld[2] - William Farley was elected with 5,679,271 votes (87.11%), and 840,205 votes (12.89%) were withheld[2] Auditor Appointment - Smythe LLP was appointed as the auditor with 7,359,275 votes (99.78%) in favor, and 16,117 votes (0.22%) were withheld[3] Stock Option Plan - The stock option plan was re-approved with 6,048,425 votes (94.33%) in favor, while 363,453 votes (5.67%) were against[4]

Exhibit 99.1 CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three months ended March 31, 2023 and 2022 (Unaudited - expressed in U.S. Dollars) XORTX THERAPEUTICS INC. Condensed Interim Consolidated Statements of Financial Position (Unaudited - expressed in U.S. Dollars) | | | | December | | | --- | --- | --- | --- | --- | | | | | 31, | January 1, | | | | | 2022 | 2022 | | | | March 31, | Restated | Restated | | | Note | 2023 | (Note 2) | (Note 2) | | | | $ | $ | | | Assets | | | | | | Current | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

Exhibit 99.3 XORTX THERAPEUTICS INC. ANNUAL INFORMATION FORM FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 MARCH 31, 2023 Unless otherwise stated, the information set forth in this AIF is as of December 31, 2022. i XORTX THERAPEUTICS INC. ANNUAL INFORMATION FORM FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 MARCH 31, 2023 REFERENCE INFORMATION TABLE OF CONTENTS In this annual information form (the "AIF"), a reference to the "Company", "XORTX", "we", "us", "our" and similar words refer to XORTX Therapeutics Inc. ...

Exhibit 99.1 CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and nine months ended September 30, 2022 and 2021 (Unaudited - expressed in Canadian Dollars) XORTX THERAPEUTICS INC. Condensed Interim Consolidated Statements of Financial Position (Unaudited - expressed in Canadian Dollars) | | | September 30, | December 31, | | --- | --- | --- | --- | | | Note | 2022 $ | 2021 $ | | Assets | | | | | Current | | | | | Cash and cash equivalents | 5 | 12,160,047 | 18,851,244 | | Accounts receivabl ...

Exhibit 99.1 CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and six months ended June 30, 2022 and 2021 (Unaudited - expressed in Canadian Dollars) XORTX THERAPEUTICS INC. Condensed Interim Consolidated Statements of Financial Position (Unaudited - expressed in Canadian Dollars) | | | | December | | --- | --- | --- | --- | | | | June 30, | 31, | | | Note | 2022 $ | 2021 $ | | Assets | | | | | Current | | | | | Cash and cash equivalents | 5 | 13,420,636 | 18,851,244 | | Accounts receivable ...

Exhibit 99.1 CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021 (Unaudited - expressed in Canadian Dollars) 1 NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS Under National Instrument 51-102, Part 4, subsection 4.3(3) (a), if an auditor has not performed a review of the condensed interim consolidated financial statements they must be accompanied by a notice indicating that the financial statements have not been reviewed b ...